Health ❯ Healthcare

Clinical Trials

Drug Development Phase 3 Trials Drug Efficacy Patient Outcomes Phase III Trials Research Studies Randomized Controlled Trials Cancer Research Efficacy Studies Cancer Treatment

AI-Supported Mammography Improves Detection and Reduces Aggressive Cases, Lancet Trial Finds

A two-year randomized study of more than 100,000 Swedish women supports cautious rollout under continuous monitoring.

Triple-Drug Combo Eradicates Pancreatic Tumors in Mice, Peer-Reviewed Study Finds

Triple-Drug Strategy Wipes Out Pancreatic Tumors in Mice, Study Finds

First Randomized Trial Finds Telesurgery Matches Local Robotic Outcomes Over Long Distances

Randomized Trial Finds Solriamfetol Improves Alertness in Early-Morning Shift Workers

Trials Show Fecal Transplants Enhance Cancer Immunotherapy, Including Longer PFS in Randomized Kidney Study

FDA Grants Breakthrough Therapy Designation to Biogen’s Litifilimab for Cutaneous Lupus

First Pivotal Trial Finds Cooled-Laser Prostate Therapy Effective at 3 Months With Low Morbidity

Lilly Strikes Up to $1.12 Billion Pact With Seamless Therapeutics for Hearing‑Loss Gene Editing

Roche’s CT-388 Shows Up to 22.5% Placebo-Adjusted Weight Loss in Phase 2 as Phase 3 Nears

FDA Grants Priority Review to Otsuka’s ADHD Drug Centanafadine With July 24 Decision Date

NICE Endorses Dupilumab as First Targeted Biologic for Uncontrolled Eosinophilic COPD

FDA Grants Priority Review to Leqembi Autoinjector for Weekly At-Home Starting Dose

Apple Watch Screening Quadruples AFib Detection in High-Risk Seniors, EQUAL RCT Finds

Moderna, Merck Melanoma Vaccine Shows Durable Five-Year Benefit as Stock Hits 52-Week High

Moderna–Merck Personalized Melanoma Vaccine Sustains 5-Year Benefit, Cutting Recurrence Risk by 49%

ImmunityBio Sets 30-Day FDA Submission After Positive Meeting on Anktiva Expansion

New Evidence Flags Rapid Weight Regain After Stopping GLP-1 Drugs

Abemaciclib Shows Early Benefit Signal in Genetically Selected High-Grade Meningioma Trial

Corvus Leaps After Soquelitinib Shows Strong Phase 1 Cohort 4 Eczema Data